BIGBEAR
PHARMACEUTICAL
Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.
AuthenticGuaranteeFast DeliveryPrivacy Alpelisib was approved by the U.S. Food and Drug Administration (FDA) in 2019 for use in combination with fulvestrant to treat hormone receptor-positi···【More】
Update: 23 Mar,2026Source: BigbearViews: 87
Alpelisib has been approved for marketing in several countries and regions, including the United States, the European Union, and Japan, but it has not···【More】
Update: 23 Mar,2026Source: BigbearViews: 88
Alpelisib, an oral small-molecule PI3Kα inhibitor from Novartis, Switzerland, offers new hope for patients with advanced or metastatic breast cancer c···【More】
Update: 23 Mar,2026Source: BigbearViews: 87
Alpelisib has relatively many adverse reactions. If not detected and treated promptly and correctly, these can have a significant impact on the patien···【More】
Update: 23 Mar,2026Source: BigbearViews: 87
Efficacy and Actions of ElacestrantElacestrant is an anti-tumor drug, belonging to the estrogen receptor antagonist class.Efficacy and Actions of Elac···【More】
Update: 18 Mar,2026Source: BigbearViews: 91
Precautions for Axitinib UseAxitinib is an oral, highly selective tyrosine kinase inhibitor developed by Pfizer, primarily used to treat advanced rena···【More】
Update: 18 Mar,2026Source: BigbearViews: 89
Dificid's Efficacy and ActionsDificid was developed by Astellas Pharma in Japan and approved by the US FDA on May 27, 2011.Dificid is a fermentati···【More】
Update: 18 Mar,2026Source: BigbearViews: 90
Apellixis is a targeted therapy for a specific type of breast cancer, developed by Novartis in Switzerland and approved by the US FDA in 2019.Precauti···【More】
Update: 18 Mar,2026Source: BigbearViews: 88
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
